Franklin Resources Inc. Boosts Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Franklin Resources Inc. raised its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 10.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,405 shares of the company’s stock after purchasing an additional 1,538 shares during the period. Franklin Resources Inc.’s holdings in Intellia Therapeutics were worth $320,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also bought and sold shares of the company. State Street Corp grew its stake in shares of Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock worth $105,700,000 after acquiring an additional 780,754 shares during the period. ARK Investment Management LLC lifted its holdings in Intellia Therapeutics by 5.7% during the third quarter. ARK Investment Management LLC now owns 12,255,440 shares of the company’s stock valued at $251,849,000 after purchasing an additional 659,651 shares during the last quarter. Federated Hermes Inc. boosted its position in Intellia Therapeutics by 19.2% during the second quarter. Federated Hermes Inc. now owns 2,300,889 shares of the company’s stock worth $51,494,000 after purchasing an additional 371,189 shares during the period. Two Sigma Advisers LP increased its stake in shares of Intellia Therapeutics by 33.5% in the third quarter. Two Sigma Advisers LP now owns 1,027,617 shares of the company’s stock worth $21,118,000 after purchasing an additional 257,700 shares in the last quarter. Finally, Sphera Funds Management LTD. raised its position in shares of Intellia Therapeutics by 108.8% in the third quarter. Sphera Funds Management LTD. now owns 291,080 shares of the company’s stock valued at $5,982,000 after purchasing an additional 151,661 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Up 2.2 %

NASDAQ NTLA opened at $11.66 on Thursday. The stock’s 50-day simple moving average is $14.23 and its two-hundred day simple moving average is $19.58. Intellia Therapeutics, Inc. has a twelve month low of $11.34 and a twelve month high of $34.87. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -2.14 and a beta of 1.76.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same quarter last year, the company posted ($1.38) earnings per share. On average, equities analysts expect that Intellia Therapeutics, Inc. will post -5.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Wells Fargo & Company cut their price objective on shares of Intellia Therapeutics from $80.00 to $70.00 and set an “overweight” rating for the company in a report on Monday, November 18th. Barclays cut their price target on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating for the company in a report on Friday, November 8th. William Blair reiterated a “neutral” rating and set a $14.00 price objective on shares of Intellia Therapeutics in a research note on Monday, November 18th. Citigroup cut their target price on Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $90.00 price target on shares of Intellia Therapeutics in a report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $54.94.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.